Member Info for goupplease

Can't believe this has got sellers ahead of agm tomorrow.
They are the nervous and cannot appreciate what's coming . We are completely derisked at this value imho

Mid 8's

There is a new firm listing on nex ,for medical cannabis having been successful in Canada , keep an eye out .
If your interested it was in the Sunday mail ,
Give me a shout if you can't find it

The rns from the Friday and Monday means nfx can talk about all three tricks ,
001,002 and Ebers ,
I expect double digits and beyond this week.
This company will eventually be sold out , don't know when
The bod have shares, small free float , main market.

BerthIe
I really like your post .
We are going foward again .
Eventually there will be a buy out , I don't have any idea when
What I do like is the bod, they shares, there's a small free float and it's main market not aim.

BerthIe
I really like your post .
We are going foward again .
Eventually there will be a buy out , I don't have any idea.
What I do like is the bod, they shares, there's a small free float and it's main market not aim.

Hopefully we can keep the volume up

You made 15% today great ,
If you panicked on yesterday's rubbish and lost the 15% rise , sorry .
15% does me , thanks
Another 15% Monday another 15% tues yum

There will be lots of questions answered at the agm .
If you keep bothering them on the phone they can't work can they ,
Plus they can't give anything out by law , just wait for the rns ,
If you doubt them don't invest.
Look at centrica it's halved this year , fine example , that's the way it goes .
Banks pay less than 1% interest

Is the volume .
Imho loads got locked in higher an they are averaging down .
There are no traders at present.
The bod have a decent amount of shares and are interested in the end game.
I think 002 is more advanced than they let on .
Your got world market on 001 plus other irons .
If you worry about sp drop tough it happens that's why if you slice at the right time you're derisked.
It's an investment , I'm in sfor for the long term as well , that's dropped from high but it's sorrell and he's building a great company, you can't win every day

Confirmation of the seller finished it should turn 10p again.

This is derisked, I don't expect great shakes for 3 months or so by the pod,then it should be very good ,
Other news will give it lifts but the biggy is 002,
All you need is patience, everyone has their own agenda .
For me you won't get better but not tomorrow , not next week , not next month,

Dan podcast all positive.
Just patience required .
More from the agm tues

Rns is the only way to believe if there's not a podcast for me

Below tells you what he has given up to join nfx
He must see new horizons to aim at .

Dr. Thillai is the Lead Clinician for the Cambridge Interstitial Lung Disease Unit. He graduated from St. Mary’s medical school in 2002 with his medical degree and a BA in medical journalism. He began his training as a junior doctor in London and Oxford where he gained Membership of the Royal College of Physicians. He was then appointed as the Infectious Diseases Fellow on the Map of Medicine project at NHS Connecting for Health and as Editor-in-Chief of Junior Dr magazine, before being awarded a personal Research Training Fellowship from the Wellcome Trust. This allowed him to undertake three years of scientific research into sarcoidosis which culminated in a PhD in Immunology and Proteomics from Imperial College London.

He continued his medical training in lung cancer, pulmonary vascular disorders and lung transplantation in Papworth and then in respiratory and general medicine at Addenbrooke’s Hospital. He subsequently completed an observership in sarcoidosis at the Cleveland Center in the USA before being appointed in 2015 as a Consultant within the Papworth Interstitial Lung Diseases Unit with a specific interest in sarcoidosis. He continues to attend a regular outpatient clinic at Addenbrooke’s Hospital and maintains ongoing research links with Imperial College London. He has been awarded a number of clinical and research prizes from societies including the Eastern Thoracic Society, Imperial College London and the National Heart and Lung Institute. He is the editor of five books, has written numerous book chapters and research papers in sarcoidosis and has given presentations at several international scientific meetings.

The company works with the seller ,
They will not want offloading before the agm

Rob ,the good thing is it was do to a seller in a period with no news ,not any bad news
All that is required is patience and belief .
This new man is going to firm up 002 and imho we could be 20 p to 25 p .but that's in the future , yesterday was such a buying opportunity, it won't be seen again

. His dynamism coupled to his proximity to the Nuformix team in his role at at Royal Papworth will facilitate real impact on NXP002 development"

Real impact on NXP002 exciting

The Internet looks like they are not on this so we should see a nice steady rise without the the per centers .
Should hold nicely into the agm and another surge from there .
Question is is the seller done ? That's what dragged this down and unsettled people .